News & Updates

Show Multimedia Only

Short-term eGFR changes on SGLT2 inhibitor unrelated to long-term trends

22 Sep 2020

The degree of the acute decline in estimated glomerular filtration rate (eGFR) following treatment with luseogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, varies widely among patients with type 2 diabetes, a recent study has found.

Short-term eGFR changes on SGLT2 inhibitor unrelated to long-term trends

22 Sep 2020

Better time in range eases painful diabetic neuropathy

20 Sep 2020

Greater time-in-range (TIR), as assessed by continuous glucose monitoring (CGM), may lessen pain in patients with diabetic peripheral neuropathy (DPN), a new study has found.

Better time in range eases painful diabetic neuropathy

20 Sep 2020

Vitamin D protects against diabetes among people with healthy sleep patterns

20 Sep 2020

Individuals with higher circulating vitamin D concentrations are better protected against type 2 diabetes, especially those with healthier sleep patterns, a study has found.

Vitamin D protects against diabetes among people with healthy sleep patterns

20 Sep 2020

$Delayed denosumab treatment may up vertebral fracture risk$

Delayed denosumab treatment may up vertebral fracture risk

17 Sep 2020 by

In patients with osteoporosis treated with denosumab, a long interval between injections could raise their risk of vertebral fracture, a UK-based retrospective study showed.

Delayed denosumab treatment may up vertebral fracture risk

17 Sep 2020

News & Updates

Filter by Specialty:

Specialty:

Short-term eGFR changes on SGLT2 inhibitor unrelated to long-term trends

Short-term eGFR changes on SGLT2 inhibitor unrelated to long-term trends

Better time in range eases painful diabetic neuropathy

Better time in range eases painful diabetic neuropathy

Vitamin D protects against diabetes among people with healthy sleep patterns

Vitamin D protects against diabetes among people with healthy sleep patterns

Delayed denosumab treatment may up vertebral fracture risk

Delayed denosumab treatment may up vertebral fracture risk